India, Feb. 13 -- An economic evaluation published in the Indian Journal of Medical Research has demonstrated that shorter, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and offer improved health outcomes compared to the currently used longer regimens in India.

The study was conducted by ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT). It assessed the cost-effectiveness of bedaquiline-based regimens-BPaL (bedaquiline, pretomanid and linezolid) and BPaLM (with moxifloxacin)-in comparison with the existing bedaquiline-containing shorter (9-11 months) and longer (18-20 months) treatment regimens used under the National TB Elimination Progra...